A low cost hand held device for use by healthcare practitioners to screen for diseases and get results in real time on their smartphone, tablet or laptop. A healthcare practitioner can have a patient blow into the sensor and one breath will be able to detect multiple diseases by using downloadable apps. The same device will be able to determine medical adherence to provide the doctor with information regarding if their patient is taking the prescribed medication properly.
Vantage mHealthcare, Inc. has developed the first non-invasive, inexpensive, mobile early disease screening and monitoring platform that works with all smartphones, tablets and laptops. The nanotechnology is covered by several patents and uses a small Bluetooth device in combination with a downloadable app for use by healthcare practitioners. One device can be used for all patients because of the replaceable filter which prevents contamination. The first application will be early screening for lung cancer. One breath can detect several different diseases on the same device. Vantage mHealthcare is a publically traded company in the United States (OTCQB: VNTH).
The product is a sensor that can be used with any mobile device and, by reading the biomarkers in a person’s breath, it can detect the earliest signs of many types of diseases.
The results are available ‘in-the-moment’ to both the healthcare practitioner and the patient. Once a disease is identified the same device can be used for monitoring the progress of the treatment protocol by the HCP including providing oncologists with real time results on the protocol treatment they are using.
The same device can be used to monitor medical adherence by the patient. In addition the same device can be used to detect both legal and illegal narcotics in real time.
This technology received the distinguished NASA Product Innovation of the Year in April 2013.
The Vantage business model delivers value to all parties (HCPs, Pharmacy, Patients, Insurance Companies and other Payers such as Walmart and other large employers that self-fund their insurance programs)
Our first human trials are being conducted by the Scripps Translational Science Institute in California.
Our Board of Directors includes Chairman Steven Steinhubl, Director of Digital Medicine at the (STSI), who works directly with Eric Topol, one of the most recognizable forces in digital medicine in the world today; Joseph C. Peters, former Drug Czar to the White House Office of Homeland Security under President’s Clinton and Bush where he was involved in integrating technology into collaborative federal, state and local law enforcement operations; Edward Rollins, renowned public and corporate relations strategist and well-known former advisor to four U.S. Presidents; and Tony van Bijleveld, General Manager for Patheon/DPX, and former General Manager Europe for Alliance Boots Walgreens.